Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single ‐arm, open‐label phase 2 study
ConclusionsAzacitidine was safe and effective in Chinese patients with HR‐MDS. Clinical outcomes were comparable to those for primarily Caucasian patients in the phase 3 AZA‐001 study. Cmax differences between Chinese and North American patients were not associated with differences in TEAE frequency or severity. No initial azacitidine dose adjustment is required for Chinese patients with HR‐MDS.
Source: Asia-Pacific Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Xin Du, Yue ‐Yun Lai, Zhijian Xiao, Ting Liu, Yu Hu, Aining Sun, Xiao Li, Zhi‐Xiang Shen, Jie Jin, Li Yu, Eric Laille, Qian Dong, Stephen Songer, C.L. Beach Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer & Oncology | China Health | Hematology | History of Medicine | Myelodysplastic Syndrome | Study | Thrombocytopenia | USA Health